EFFICACY AND SAFETY OF THE PROPOSED BIOSIMILAR AFLIBERCEPT, SDZ-AFL, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION 52-Week Results From the Phase 3 Mylight Study
Information
- Show
- FrequencyUpdated weekly
- Published22 October 2024 at 20:37 UTC
- Length8 min
- RatingClean